For example, adjuvant or salvage epidermal growth factor receptor tyrosine kinase inhibitors were introduced, which are more effective than chemotherapy for patients with EGFR-mutant NSCLC.25 This may mask the effects of PORT, but it was not considered when the trial was initially designed. Here, EGFR is linked to non-small cell lung carcinoma.